JP2016524608A - メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防 - Google Patents

メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防 Download PDF

Info

Publication number
JP2016524608A
JP2016524608A JP2016514429A JP2016514429A JP2016524608A JP 2016524608 A JP2016524608 A JP 2016524608A JP 2016514429 A JP2016514429 A JP 2016514429A JP 2016514429 A JP2016514429 A JP 2016514429A JP 2016524608 A JP2016524608 A JP 2016524608A
Authority
JP
Japan
Prior art keywords
disease
composition
menthol
icilin
linalool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016514429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524608A5 (enExample
Inventor
スサナ カマチョ，
スサナ カマチョ，
ゴンザレス， ステファニー ミヒリク
ゴンザレス， ステファニー ミヒリク
クトレ， ヨハネス ル
クトレ， ヨハネス ル
ヘンリー マークラム，
ヘンリー マークラム，
マウリツィオ ペッツォーリ，
マウリツィオ ペッツォーリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2016524608A publication Critical patent/JP2016524608A/ja
Publication of JP2016524608A5 publication Critical patent/JP2016524608A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016514429A 2013-05-24 2014-05-23 メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防 Pending JP2016524608A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827243P 2013-05-24 2013-05-24
US61/827,243 2013-05-24
PCT/EP2014/060632 WO2014187942A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin

Publications (2)

Publication Number Publication Date
JP2016524608A true JP2016524608A (ja) 2016-08-18
JP2016524608A5 JP2016524608A5 (enExample) 2017-06-29

Family

ID=50819727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016514429A Pending JP2016524608A (ja) 2013-05-24 2014-05-23 メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防

Country Status (8)

Country Link
US (1) US20160108004A1 (enExample)
EP (1) EP3003291A1 (enExample)
JP (1) JP2016524608A (enExample)
CN (1) CN105228602A (enExample)
AU (1) AU2014270338A1 (enExample)
BR (1) BR112015028516A2 (enExample)
CA (1) CA2908402A1 (enExample)
WO (1) WO2014187942A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530751A (ja) * 2016-10-11 2019-10-24 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6719574B2 (ja) 2016-02-22 2020-07-08 ニュートリシャス ベー．フェー．Ｎｅｗｔｒｉｃｉｏｕｓ Ｂ．Ｖ． 神経変性疾患の、予防または治療のための組成物
CN109674851A (zh) * 2017-10-18 2019-04-26 大江生医股份有限公司 薄荷精油的应用
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
JP7641973B2 (ja) * 2020-03-24 2025-03-07 中国▲医▼薬大学 神経変性疾患及び脳卒中を改善する外用組成物の調製に用いられるメントールの用途
JP7194484B2 (ja) * 2020-10-21 2022-12-22 三井農林株式会社 脳機能改善剤
CN116919930A (zh) * 2022-04-06 2023-10-24 沈阳药科大学 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
JP2006199647A (ja) * 2005-01-21 2006-08-03 Japan Health Science Foundation 脂肪細胞分化制御剤
JP2007302572A (ja) * 2006-05-09 2007-11-22 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
JP2008231049A (ja) * 2007-03-22 2008-10-02 Saburo Yasuda アポトーシス誘導物質
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
KR20110134961A (ko) * 2010-06-10 2011-12-16 고려대학교 산학협력단 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137818A1 (en) * 2008-05-09 2009-11-12 Mount Sinai School Of Medicine Of New York University Methods for preventing and treating neurodegenerative diseases
EP2846815A4 (en) * 2012-05-07 2016-01-20 Israel State GERANIUM OIL AND INGREDIENTS THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE ILLNESSES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
JP2006199647A (ja) * 2005-01-21 2006-08-03 Japan Health Science Foundation 脂肪細胞分化制御剤
JP2007302572A (ja) * 2006-05-09 2007-11-22 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
JP2008231049A (ja) * 2007-03-22 2008-10-02 Saburo Yasuda アポトーシス誘導物質
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
KR20110134961A (ko) * 2010-06-10 2011-12-16 고려대학교 산학협력단 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PERRY N S L, JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. V52, JPN5016005823, 20 March 2000 (2000-03-20), GB, pages 895 - 902, ISSN: 0003906764 *
VINCENT A M, AMYOTROPHIC LATERAL SCLEROSIS., vol. V6 N1, JPN5016005822, 1 January 2005 (2005-01-01), GB, pages 29 - 36, ISSN: 0003906763 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530751A (ja) * 2016-10-11 2019-10-24 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
JP7225103B2 (ja) 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
JP2023058599A (ja) * 2016-10-11 2023-04-25 ジービーエス グローバル バイオファーマ，インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
US11980592B2 (en) 2016-10-11 2024-05-14 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20160108004A1 (en) 2016-04-21
CA2908402A1 (en) 2014-11-27
BR112015028516A2 (pt) 2017-07-25
EP3003291A1 (en) 2016-04-13
WO2014187942A1 (en) 2014-11-27
CN105228602A (zh) 2016-01-06
AU2014270338A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
JP2016524608A (ja) メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防
Coelho et al. Zinc as a possible treatment for tinnitus
AU2019222781B2 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
JP2016524609A (ja) メントール及び／又はイシリンを用いるうつ病の処置又は予防
US11241433B2 (en) Treatment or prevention of autism disorders using menthol, linalool and/or icilin
CN110475553A (zh) 减轻未患痴呆的个体的认知衰老的组合物和方法
US20210121489A1 (en) Prophylaxis and treatment of cognitive dysfunction and decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181030